XML 45 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net (loss) income $ (20,619) $ 10,333
Adjustments to reconcile net (loss) income to cash flows from operating activities:    
Depreciation and amortization 47,486 42,048
Share-based compensation expense 32,758 16,690
Excess tax benefit from share-based compensation (6,984) (11,730)
Impairment of long-lived assets   3,346
(Gain) loss on sale of property, plant and equipment (12,160) 391
(Gain) on sale of investment of Acceleron Pharma Inc. (15,296)  
Deferred income taxes (10,664) (1,732)
Loss on debt refinancing transaction   7,541
Prepayment penalty in connection with debt refinancing   (3,733)
Other non-cash charges 9,965 1,169
Changes in assets and liabilities:    
Receivables (5,162) (10,743)
Inventory, prepaid expenses and other assets (19,714) (1,036)
Accounts payable and accrued expenses 3,693 16,929
Deferred revenue (1,304) (974)
Other long-term liabilities 3,306 (448)
Cash flows provided by operating activities 5,305 68,051
CASH FLOWS FROM INVESTING ACTIVITIES:    
Additions of property, plant and equipment (11,438) (11,884)
Proceeds from the sale of property, plant and equipment 14,361 125
Purchases of investments (433,203) (175,619)
Sales and maturities of investments 184,446 70,149
Cash flows used in investing activities (245,834) (117,229)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from the issuance of ordinary shares, net 248,406  
Proceeds from the issuance of ordinary shares under share-based compensation arrangements 21,821 31,926
Excess tax benefit from share-based compensation 6,984 11,730
Employee taxes paid related to net share settlement of equity awards (12,546) (8,523)
Principal payments of long-term debt (3,376) (5,450)
Cash flows provided by financing activities 261,289 29,683
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 20,760 (19,495)
CASH AND CASH EQUIVALENTS - Beginning of period 167,562 135,892
CASH AND CASH EQUIVALENTS - End of period 188,322 116,397
Non-cash investing and financing activities:    
Purchased capital expenditures included in accounts payable and accrued expenses $ 1,491 $ 1,056